IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1076-1100 out of 1250.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

Public Release: 26-Mar-2014
Science Translational Medicine
Some breast cancer tumors hijack patient epigenetic machinery to evade drug therapy
A breast cancer therapy that blocks estrogen synthesis to activate cancer-killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute.
Alexander von Humboldt Foundation, US Department of Defense, National Institutes of Health, Susan G. Komen Foundation

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 26-Mar-2014
New England Journal of Medicine
New drug successfully treats crizotinib-resistant, ALK-positive lung cancer
Now a new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.
Novartis, NIH/National Cancer Institute, V Foundation for Cancer Research, Be a Piece of the Solution, Evan Spirito Memorial Founndation

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 26-Mar-2014
BJU International
Certain genetic variants may put bladder cancer patients at increased risk of recurrence
In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment. A new study published in BJU International indicates that inheriting certain DNA sequences can affect a patient's prognosis.

Contact: Evelyn Martinez
emartinez@wiley.com
201-748-6358
Wiley

Public Release: 25-Mar-2014
European Physical Journal D
Plasma tool for destroying cancer cells
Plasma medicine is a new and rapidly developing area of medical technology. Specifically, understanding the interaction of so-called atmospheric pressure plasma jets with biological tissues could help to use them in medical practice. Under the supervision of Sylwia Ptasinska, Xu Han and colleagues conducted a quantitative and qualitative study of the different types of DNA damage induced by atmospheric pressure plasma exposure. The paper is published in European Physical Journal D.
National Science Foundation

Contact: Saskia Rohmer
saskia.rohmer@springer.com
49-622-148-78414
Springer

Public Release: 25-Mar-2014
JAMA
Treatment helps reduce risk of esophagus disorder progressing to cancer
Among patients with the condition known as Barrett's esophagus, treatment of abnormal cells with radiofrequency ablation (use of heat applied through an endoscope to destroy cells) resulted in a reduced risk of this condition progressing to cancer, according to a study in the March 26 issue of JAMA.

Contact: Jacques J. Bergman, M.D., Ph.D.
j.j.bergman@amc.uva.nl
The JAMA Network Journals

Public Release: 25-Mar-2014
Angewandte Chemie International Edition
New drug raises potential for cancer treatment revolution
A revolution in cancer treatment could soon be underway following a breakthrough by the University of Warwick that may lead to a dramatic improvement in cancer survival rates.

Contact: Tom Frew
a.t.frew@yahoo.co.uk
44-024-765-75910
University of Warwick

Public Release: 25-Mar-2014
The Lancet Oncology
Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.
Cancer Research UK, European Organisation for Research and Treatment of Cancer Charitable Trust, United Kingdom National Health Service, Canadian Cancer Society Research Institute, Amgen

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 25-Mar-2014
Journal of Clinical Investigation
JCI online ahead of print table of contents for March 25, 2014
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, March 25, 2014 in the JCI: 'Epigenetic alterations disrupt intestinal T cell homeostasis,' 'Researchers develop a conditionally immortalized human β cell line, PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors,' 'Sphingosine-1-phosphate receptor 1 reporter mice reveal receptor activation sites in vivo,' 'Leptin-promoted cilia assembly is critical for normal energy balance,' and more.

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 25-Mar-2014
Journal of Nutritional Biochemistry
Texas researcher: Peaches inhibit breast cancer metastasis in mice
Lab tests at Texas A&M AgriLife Research have shown that treatments with peach extract inhibit breast cancer metastasis in mice.
Vegetable and Fruit Improvement Center at Texas A&M, US Department of Agriculture, California Tree Fruit Agreement

Contact: Kathleen Phillips
ka-phillips@tamu.edu
979-845-2872
Texas A&M AgriLife Communications

Public Release: 25-Mar-2014
Journal of Clinical Oncology
Twenty-five percent of breast cancer survivors report financial decline due to treatment
Four years after being treated for breast cancer, a quarter of survivors say they are worse off financially, at least partly because of their treatment, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.
NIH/National Cancer Institute, American Cancer Society

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 24-Mar-2014
International Journal of Radiation Oncology
Radiation therapy and cancer vaccines: Timing is everything
Combining radiation with immnotherapy can boost cancer killing. Now a team from Thomas Jefferson University has shown that the boost works best when the therapies are sequenced correctly.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-847-5884
Thomas Jefferson University

Public Release: 24-Mar-2014
Proceedings of the National Academy of Sciences
Deletion of FAT10 gene reduces body fat, slows down aging in mice
A single gene appears to play a crucial role in coordinating the immune system and metabolism, and deleting the gene in mice reduces body fat and extends lifespan, according to new research by scientists at the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University and Yale University School of Medicine.
National Institutes of Health

Contact: Andrea Grossman
617-636-3728
Tufts University, Health Sciences Campus

Public Release: 24-Mar-2014
Journal of Cell Biology
p53 cuts off invading cancer cells
The tumor suppressor p53 does all it can to prevent oncogenes from transforming normal cells into tumor cells. Sometimes oncogenes manage to initiate tumor development in the presence of p53, but the tumor suppressor doesn't give up and focuses its efforts instead on limiting the tumor's ability to invade and metastasize. Researchers uncover one way that p53 acts to prevent cancer cell invasion.
National Research Foundation Singapore, Ministry of Education Singapore, and others

Contact: Rita Sullivan King
news@rupress.org
212-327-8603
Rockefeller University Press

Public Release: 24-Mar-2014
Society of Interventional Radiology 39th Annual Scientific Meeting
Journal of Vascular and Interventional Radiology
Y-90 provides new, safe treatment for metastatic breast cancer
A minimally invasive treatment that delivers cancer-killing radiation directly to tumors shows promise in treating breast cancer that has spread to the liver when no other treatment options remain. The outpatient treatment, called yttrium-90 (Y-90) radioembolization, was safe and provided disease stabilization in 98.5 percent of the women's treated liver tumors.

Contact: Ellen Acconcia
eacconcia@sirweb.org
703-460-5582
Society of Interventional Radiology

Public Release: 24-Mar-2014
Society of Interventional Radiology 39th Annual Scientific Meeting
Journal of Vascular and Interventional Radiology
New implant shows promise for painful osteoporotic spine fractures
Individuals suffering from spinal fractures -- caused by osteoporosis or weakened bones -- now have another option to reduce pain, restore function and improve quality of life, according to a study of 300 patients treated with a new type of vertebral augmentation. Results of a randomized, controlled multicenter trial on a new implant treatment for vertebral compression fractures are being reported for the first time at the Society of Interventional Radiology's 39th Annual Scientific Meeting.

Contact: Ellen Acconcia
eacconcia@sirweb.org
703-460-5582
Society of Interventional Radiology

Public Release: 24-Mar-2014
72nd Annual Meeting of the American Academy of Dermatology
Increased awareness about skin cancer needed for minorities
More awareness about skin cancer is needed for minorities because they believe they are at low risk of developing it, says Henry Ford Hospital dermatologist Diane Jackson-Richards, M.D.

Contact: David Olejarz
David.Olejarz@hfhs.org
313-874-4094
Henry Ford Health System

Public Release: 24-Mar-2014
Advanced Functional Materials
Hot nanoparticles for cancer treatments
Nanoparticles have a great deal of potential in medicine: for diagnostics, as a vehicle for active substances or a tool to kill off tumours using heat. ETH Zurich researchers have now developed particles that are relatively easy to produce and have a wide range of applications.

Contact: Georgios Sotiriou
sotiriou@hsph.harvard.edu
617-784-5506
ETH Zurich

Public Release: 24-Mar-2014
Clinical Genetics
Researchers issue state-of-the-state on genetic-based testing and treatment for breast cancer
Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer. The paper entitled 'Personalized Therapy for Breast Cancer' was accepted on March 17, 2014, for publication in Clinical Genetics. The paper discusses targeted therapies, new biomarkers, and the quality of commercially available testing methods.

Contact: Donna Dubuc
donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth

Public Release: 24-Mar-2014
Journal of Clinical Oncology
Oncologists differ widely on offering cancer gene testing, study finds
Many cancer researchers believe that cutting-edge advances in genomics will pave the way for personalized or 'precision' cancer medicine for all patients in the near future. A new study by researchers at Dana-Farber Cancer Institute, however, suggest that not all doctors are ready to embrace tests that look for hundreds of DNA changes in patients' tumor samples, while others plan to offer this type of cancer gene testing to most of their patients. The findings are published in the Journal of Clinical Oncology.
NIH/National Human Genome Research Institute, American Cancer Society

Contact: Anne Doerr
Anne_Doerr@DFCI.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 24-Mar-2014
Gastroenterology
Bundled payments come to gastroenterology
Patients want physicians to provide high-quality care and the health system requires good value for physician work. To help gastroenterologists achieve these goals, the American Gastroenterological Association (AGA) has developed a colonoscopy bundled payment model, which has been published in Gastroenterology, the official journal of the AGA.

Contact: Aimee Frank
afrank@gastro.org
301-941-2620
American Gastroenterological Association

Public Release: 24-Mar-2014
Nature
Gene implicated in progression and relapse of deadly breast cancer finding points to potential Achilles' heel in triple negative breast cancer
Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options. Their research, published in this week's Nature, suggests that targeting the gene may be a new approach to treating the disease.

Contact: Jen Gundersen
jeg2034@med.cornell.edu
646-317-7402
Weill Cornell Medical College

Public Release: 24-Mar-2014
Cancer
Use of mood-stabilizing drug linked with reduced risk of developing head and neck cancer
A new study indicates that a commonly used mood stabilizing drug may help prevent head and neck cancer. The study is published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

Contact: Evelyn Martinez
emartinez@wiley.com
201-748-6358
Wiley

Public Release: 23-Mar-2014
Nature Genetics
TGen-led study discovers genetic cause of rare type of ovarian cancer
The cause of a rare type of ovarian cancer that most often strikes girls and young women has been uncovered by an international research team led by the Translational Genomics Research Institute, according to a study published online today by the renowned scientific journal, Nature Genetics. The findings revealed a 'genetic superhighway' mutation in a gene found in the overwhelming majority of patients with small cell carcinoma of the ovary, hypercalcemic type, or SCCOHT.

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 23-Mar-2014
Nature Methods
'MaMTH' advance: New technology sheds light on protein interactions
Scientists have a better way to study human proteins -- large molecules that are part of every cell in the body -- thanks to a new technology developed by University of Toronto researchers. The technology tracks a class of proteins called membrane proteins as they interact with other proteins to either maintain health or contribute to disease.
Ontario Genomics Institute, Canadian Institutes of Health Research, Canadian Cancer Society

Contact: Jim Oldfield
jim.oldfield@utoronto.ca
416-946-8423
University of Toronto

Public Release: 23-Mar-2014
Society of Gynecological Oncology 45th Annual Meeting on Women's Cancer
HPV eradicated by AHCC supplement, preclinical study suggests
HPV, human papilloma virus, was eradicated by AHCC, a Japanese mushroom extract, in vivo and in vitro, in preclinical research presented by Judith A. Smith, PharmD., at Society of Gynecological Oncology 45th Annual Meeting on Women's Cancer in Tampa. These data suggest AHCC can eliminate HPV infections and may have a role in the prevention of HPV-related cancers. A confirmatory pilot study in HPV+ women is underway at UTHealth Women's Center.

Contact: John Carney or Julie McQuain
JMPRmedia@aol.com
212-477-0472
JMPR Associates, Inc.

Showing releases 1076-1100 out of 1250.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

  Search News Releases

     

 

 

EurekAlert!